BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28346917)

  • 1. Endocrine Long-Term Follow-Up of Children with Neurofibromatosis Type 1 and Optic Pathway Glioma
.
    Sani I; Albanese A
    Horm Res Paediatr; 2017; 87(3):179-188. PubMed ID: 28346917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
    Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optic chiasm glioma in children: Endocrine disorders in 14 cases].
    García García E; Márquez Vega C; Fajardo Cascos M; Venegas Moreno E; Soto Moreno A
    Med Clin (Barc); 2016 May; 146(10):446-9. PubMed ID: 26971985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
    J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optic pathway glioma and endocrine disorders in patients with and without NF1.
    Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
    Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibromatosis type 1 and optic pathway glioma. A long-term follow-up.
    Lama G; Esposito Salsano M; Grassia C; Calabrese E; Grassia MG; Bismuto R; Melone MA; Russo S; Scuotto A
    Minerva Pediatr; 2007 Feb; 59(1):13-21. PubMed ID: 17301720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
    Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
    Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma.
    Collet-Solberg PF; Sernyak H; Satin-Smith M; Katz LL; Sutton L; Molloy P; Moshang T
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):79-85. PubMed ID: 9302376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
    Falzon K; Drimtzias E; Picton S; Simmons I
    Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE; Nuding MA
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.
    Cambiaso P; Galassi S; Palmiero M; Mastronuzzi A; Del Bufalo F; Capolino R; Cacchione A; Buonuomo PS; Gonfiantini MV; Bartuli A; Cappa M; Macchiaiolo M
    Am J Med Genet A; 2017 Sep; 173(9):2353-2358. PubMed ID: 28631895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1.
    Cnossen MH; Stam EN; Cooiman LC; Simonsz HJ; Stroink H; Oranje AP; Halley DJ; de Goede-Bolder A; Niermeijer MF; de Muinck Keizer-Schrama SM
    Pediatrics; 1997 Oct; 100(4):667-70. PubMed ID: 9310522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optic Gliomas in Neurofibromatosis Type 1.
    Parkhurst E; Abboy S
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):334-338. PubMed ID: 27537249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
    Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
    J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
    Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
    Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
    Thiagalingam S; Flaherty M; Billson F; North K
    Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prechiasmatic transection of the optic nerve in optic nerve glioma: technical description and surgical outcome.
    Borghei-Razavi H; Shibao S; Schick U
    Neurosurg Rev; 2017 Jan; 40(1):135-141. PubMed ID: 27230830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible Growth Hormone Excess in Two Girls with Neurofibromatosis Type 1 and Optic Pathway Glioma.
    Bruzzi P; Sani I; Albanese A
    Horm Res Paediatr; 2015; 84(6):414-22. PubMed ID: 26488470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Morbidity After Pediatric Optic Gliomas: A Longitudinal Analysis of 166 Children Over 30 Years.
    Gan HW; Phipps K; Aquilina K; Gaze MN; Hayward R; Spoudeas HA
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3787-99. PubMed ID: 26218754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
    Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
    Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.